IDEXX Laboratories, Inc. $IDXX Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.6% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 911,489 shares of the company’s stock after buying an additional 39,700 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in IDEXX Laboratories were worth $479,844,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. New Mexico Educational Retirement Board raised its position in shares of IDEXX Laboratories by 8.2% in the 2nd quarter. New Mexico Educational Retirement Board now owns 3,950 shares of the company’s stock worth $2,079,000 after buying an additional 300 shares during the period. Mufg Securities Americas Inc. grew its position in IDEXX Laboratories by 7.5% during the second quarter. Mufg Securities Americas Inc. now owns 2,376 shares of the company’s stock valued at $1,251,000 after acquiring an additional 166 shares during the period. Nissay Asset Management Corp Japan grew its position in IDEXX Laboratories by 4.7% during the second quarter. Nissay Asset Management Corp Japan now owns 23,713 shares of the company’s stock valued at $12,483,000 after acquiring an additional 1,056 shares during the period. Pin Oak Investment Advisors Inc. acquired a new stake in IDEXX Laboratories during the second quarter worth about $49,000. Finally, Livforsakringsbolaget Skandia Omsesidigt acquired a new stake in IDEXX Laboratories during the second quarter worth about $210,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently weighed in on IDXX. UBS Group lifted their price objective on IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday. Barclays cut their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. Citigroup lifted their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. Finally, Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Six investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $747.00.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $554.99 on Monday. The stock has a fifty day moving average price of $559.01 and a 200 day moving average price of $573.33. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 12-month low of $518.55 and a 12-month high of $769.98. The company has a market cap of $43.72 billion, a P/E ratio of 39.03, a P/E/G ratio of 2.96 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, topping analysts’ consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The company had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.20 billion. During the same quarter in the previous year, the firm posted $3.50 earnings per share. The firm’s quarterly revenue was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Research analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.